A once-daily pill shows potential to ease motor “off” periods and sleep issues, signaling a shift beyond dopamine in Parkinson’s care.
People with Parkinson’s disease know too well how it goes. Medication is taken on time, routines are followed and yet, without warning, the body simply stops cooperating. A hand stiffens. A step falters. Words slow down. Clinicians call it “OFF time.” Patients call it a break in continuity, a pause in control.
This is the space clinical-stage pharmaceutical company Cerevance is trying to reach with solengepras, an investigational, once-daily pill that, in Phase 2 trials, has shown it can meaningfully reduce these OFF periods.
The company will present the data at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, adding fresh momentum to a field that has long relied on the same playbook [1].
Breaking from a decades-old strategy
Most Parkinson’s drugs work by boosting dopamine, the brain chemical that helps coordinate movement. It is a logical target. Parkinson’s is, in part, defined by its loss. However, the strategy has limits. Over time, dopamine-based treatments can become less predictable, wearing off faster and triggering side effects like involuntary movements. What begins as relief can turn into a balancing act.
Solengepras takes a different route. Instead of trying to replace dopamine, it adjusts the circuitry around it. Think of the brain’s movement system as a set of interconnected roads. Dopamine is a major highway, but it is not the only way through. Solengepras works on a side route: a receptor called GPR6, which helps regulate the flow of signals without adding more dopamine to the system. The idea is to restore balance, rather than overload a single pathway.
In the Phase 2 studies, patients taking solengepras experienced reductions in daily OFF time. More minutes, even hours, where movement felt steadier and more reliable.
The signal did not stop there. The drug also showed potential to improve sleep disturbances, a symptom that often sits in the background of Parkinson’s but shapes everyday life just as deeply. Poor sleep can amplify fatigue, cloud thinking and make motor symptoms harder to manage the next day.
At the AAN meeting, two poster presentations will explore these outcomes in more detail – one led by Dr Robert Hauser, focusing on OFF-time improvements, and another by Dr Harini Sarva, examining sleep-related effects. Together, they hint at a treatment that does not just smooth movement, but touches the rhythms of daily living.
Parkinson’s is the fastest-growing neurological disorder in the world, affecting more than 10 million people globally. As populations age, that number is expected to rise. Yet innovation has been incremental. Many therapies still circle around dopamine, refining rather than reimagining the approach.
What makes solengepras noteworthy is its results and framing. It treats Parkinson’s less as a single-chemical deficiency and more as a systems-level imbalance. That perspective aligns with a broader shift happening across longevity science: moving away from single-target fixes toward interventions that restore balance across complex biological systems.
The road to Phase 3
Of course, Phase 2 success is only part of the story. Solengepras is now being tested in a larger, global Phase 3 study called ARISE, involving around 330 patients who experience at least three hours of OFF time per day. Over 12 weeks, researchers will track whether the drug consistently reduces these periods while also improving other aspects of life, such as sleep and cognition.
It is a higher bar and the one that ultimately determines whether a therapy can move from promise to practice. Still, the design itself reflects a more holistic ambition.
Now, looking into the longevity lens on Parkinson’s, at its core, it’s a disease of time not just in how it progresses, but in how it fragments the day – into ON moments and OFF ones, into periods of clarity and interruption.
The conversation meets longevity. Extending lifespan has little meaning if those extra years are defined by unpredictability and loss of control. What matters is continuity. The ability to move, to rest, to think, to live without constant disruption.
By reducing OFF time and potentially improving sleep, solengepras is, in a sense, giving time back. That may be where the future of Parkinson’s treatment and longevity more broadly is headed, toward therapies that quietly restore balance across the systems that make us function.
The upcoming AAN presentations will offer a closer look at how solengepras performs across different symptoms and patient groups. For now, the data moves beyond dopamine and toward a more nuanced understanding of the disease.
